Pfizer Announces Positive Midstage Trial Results for Next-Generation Pneumococcal Vaccine
In a midstage study, Pfizer's next-generation pneumococcal vaccine outperformed its $6 billion franchise product Prevnar 20. The trial compared four doses of the new vaccine in infants to those receiving Prevnar 20 at various intervals.
Tickers: $PFE